Pharmacogenomics News and Research RSS Feed - Pharmacogenomics News and Research

The terms pharmacogenomics and pharmacogenetics are often used interchangeably to describe a field of research focused on how genes affect individual responses to medicines. Whether a medicine works well for you—or whether it causes serious side effects—depends, to a certain extent, on your genes.

Just as genes contribute to whether you will be tall or short, black-haired or blond, your genes also determine how you will respond to medicines. Genes are like recipes—they carry instructions for making protein molecules. As medicines travel through your body, they interact with thousands of proteins. Small differences in the composition or quantities of these molecules can affect how medicines do their jobs.

These differences can be due to diet, level of activity, or the medicines a person takes, but they can also be due to differences in genes. By understanding the genetic basis of drug responses, scientists hope to enable doctors to prescribe the drugs and doses best suited for each individual.
Patient's gene profile influences effects of statins

Patient's gene profile influences effects of statins

The Montreal Heart Institute Research Centre is once again pushing the limits of knowledge in personalized medicine. A meta-analysis combining the results of several pharmacogenomic studies and involving over 40,000 research subjects now makes it possible to demonstrate a different response to statins according to the patient's gene profile. [More]
Genome Canada awards $6M grant to CAMH and Assurex Health

Genome Canada awards $6M grant to CAMH and Assurex Health

Assurex Health and Canada's Centre for Addiction and Mental Health (CAMH) today announced they have received a $6 million grant from Genome Canada, an agency of the Canadian government, to study the benefits of genetic testing to guide medication decisions for patients with depression or schizophrenia. [More]
Case Western Reserve researcher lands Director's New Innovator Awards from NIH

Case Western Reserve researcher lands Director's New Innovator Awards from NIH

For the second consecutive year, a Case Western Reserve University School of Medicine researcher has landed one of the year's much-coveted Director's New Innovator Awards from the National Institutes of Health. Principal investigator Rong Xu, PhD, assistant professor of medical informatics, will receive $2,377,000 for five years, starting immediately, to initiate computational analysis of thousands of drugs and their effects. [More]
New avenues for treatment of Alzheimer's disease

New avenues for treatment of Alzheimer's disease

Judes Poirier, PhD, C.Q., from the Douglas Mental Health Institute and McGill University in Montr-al (Canada) and his team have discovered that a relatively frequent genetic variant actually conveys significant protection against the common form of Alzheimer's disease and can delay the onset of the disease by as much as 4 years. [More]
Agena Bioscience expands ultrasensitive somatic mutation detection technology

Agena Bioscience expands ultrasensitive somatic mutation detection technology

Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., today announced expansion of the UltraSEEK™ technology, the first ultrasensitive somatic mutation detection technology for high-throughput and definitive interrogation of rare mutations that occur at less than 1% abundance in matched tissue, circulating plasma, and tumor samples. [More]
Agena Bioscience acquires Sequenom’s Bioscience business

Agena Bioscience acquires Sequenom’s Bioscience business

Agena Bioscience, Inc., a portfolio company of Telegraph Hill Partners (THP), today acquired the Bioscience business of Sequenom, Inc., which sells the MassARRAY® System for mass spectrometry-based detection of nucleic acids in research and clinical laboratories. [More]
GEN Publishing introduces semi-monthly digital publication focusing on OMICs technologies

GEN Publishing introduces semi-monthly digital publication focusing on OMICs technologies

GEN Publishing recently introduced Clinical OMICs a semi-monthly digital publication focusing on the application of OMICs technologies in clinical settings. These advanced techniques, such as next-gen sequencing, are beginning to transform medical care just as they revolutionized basic life science research over the past decade-and-a-half. [More]
Personalis receives CAP accreditation

Personalis receives CAP accreditation

Personalis, Inc., a leading provider of genome-based diagnostics, announced today that its onsite clinical laboratory has received accreditation from the College of American Pathologists (CAP), meeting the highest standard of excellence in clinical laboratory practices. [More]
Personalis and Inova team up to advance genomic medicine

Personalis and Inova team up to advance genomic medicine

Inova Translational Medicine Institute and Personalis, Inc. today announced a partnership to advance genomic medicine for Inova's patient population. [More]
Researchers to discuss implications of genomic sequencing at ACMG meeting

Researchers to discuss implications of genomic sequencing at ACMG meeting

Researchers from the Mayo Clinic Center for Individualized Medicine will present results of three different studies evaluating implications and feasibility of genome sequencing at the ACMG Annual Clinical Genetics Meeting this week in Nashville, Tenn. [More]
Innovative study uses pharmacogenomic test to treat patients with psychotic disorders

Innovative study uses pharmacogenomic test to treat patients with psychotic disorders

ValueOptions, Inc. a health improvement company specializing in mental and emotional well-being and recovery, and Genomind, a personalized medicine company, today announced an innovative study that uses pharmacogenomic testing to treat patients diagnosed with psychotic disorders, including schizophrenia and bipolar disorder. [More]
CHOP develops unique laboratory test to characterize genes that encode HLA molecules

CHOP develops unique laboratory test to characterize genes that encode HLA molecules

Immunogenetics experts at The Children's Hospital of Philadelphia (CHOP) have developed a unique laboratory test to characterize the genes that encode HLA molecules. The test relies on faster, more comprehensive gene sequencing technology to type human leukocyte antigens (HLAs)--complex, highly variable proteins on cell surfaces that are essential to immune function. [More]
Findings may help doctors personalize preterm birth prevention treatments

Findings may help doctors personalize preterm birth prevention treatments

New research findings may soon help doctors personalize preterm birth prevention treatments by identifying which women at higher risk for preterm birth will be helped by progesterone injections. [More]
ACM Global acquires Phoenix PCS to expand operation in the Asia Pacific region

ACM Global acquires Phoenix PCS to expand operation in the Asia Pacific region

ACM Global Central Laboratory, a diagnostic central laboratory specializing in delivering high quality testing services which optimize clinical trial outcomes, today announced it has acquired Phoenix Pharma Central Services Pte. Ltd, a premier central laboratory services provider for Asia Pacific clinical trials, with laboratory facilities in Singapore and Shanghai, China. The acquisition enables ACM Global to deliver increased operational and financial efficiencies to clients conducting clinical studies in the Asia Pacific region. Terms of the transaction were not disclosed. [More]
Study could lead towards a personalised medicine for chemoresistant lymphomata

Study could lead towards a personalised medicine for chemoresistant lymphomata

To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata. [More]
Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

People inherit different versions of any particular gene, and some genes affect how patients process and metabolize medicines. This especially holds true for people with cardiovascular (CV) disease. They may be fast, slow or non-metabolizers and might also react badly (with serious adverse events) to certain drug therapies or not at all. [More]
Cardiologists question FDA recommendations on genetic testing before taking Plavix

Cardiologists question FDA recommendations on genetic testing before taking Plavix

Which antiplatelet medication is best after a coronary stent? The costly and potential life-or-death question lingers after most of the 600,000 angioplasties performed every year in the United States. The answer may lie in your genes, but professional cardiovascular societies and many working cardiologists question the U.S. Food and Drug Administration's recent recommendation that patients undergo genetic testing before taking Plavix (clopidogrel bisulfate). [More]
Kaiser Permanente researchers named co-recipients of Drug Therapy Research Literature Award

Kaiser Permanente researchers named co-recipients of Drug Therapy Research Literature Award

Three Kaiser Permanente Colorado researchers have been named co-recipients of the prestigious Drug Therapy Research Literature Award, an award presented annually by the American Society of Health-System Pharmacists Foundation. [More]
STSI receives $29M grant to support innovative research on genomics, wireless technology and bioinformatics

STSI receives $29M grant to support innovative research on genomics, wireless technology and bioinformatics

The National Institutes of Health has renewed its prestigious Clinical and Translational Science Award (CTSA) with the Scripps Translational Science Institute (STSI) in the amount of $29 million over the next five years to support innovative research in genomics, wireless technology and bioinformatics toward individualizing medicine. [More]
Personalis launches early access program to Personalis ACE Clinical Exome

Personalis launches early access program to Personalis ACE Clinical Exome

Personalis, Inc., the leading provider of advanced medical exome and genome sequencing and interpretation services today announced the launch of an early access program to the Personalis ACE Clinical Exome, a single test that integrates enhanced exome sequencing with genome-wide structural variant detection to increase diagnostic yield. [More]